Tempest Therapeutics
TPST | NASDAQ
$0.50
-$0.03 (-6.23%)
At close: Oct 30, 2026, 4:00 PM ET
Tempest Therapeutics Company Profile
Company profile explainedCompany Profile
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Key Executives
| Name | Position |
|---|---|
| Matthew Angel | Chief Executive Officer, President & Director |
| Andrew Fang | Head of Business Development |
| Justin Trojanowski | VP of Finance, Corp. Controller, Treasurer, Secretary and Principal Financial & Accounting Officer |
| Nicholas J. Rossettos | CFO, Principal Financial & Accounting Officer, Treasurer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 3 | Filing |
| Oct 02, 2026 | 424B3 | Filing |
| Oct 01, 2026 | EFFECT | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 25, 2026 | S-3 | Filing |
| Sep 17, 2026 | 8-K | Current Report |
| Sep 16, 2026 | DEFA14A | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 8-K | Current Report |
Tempest Therapeutics
| Country | United States |
| IPO Date | Nov 12, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Matthew Angel |
Contact Details
2000 Sierra Point Parkway Brisbane,
California 94005 United States
Stock Details
| Ticker Symbol | TPST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001544227 |
| CUSIP Number | 87978U207 |
| ISIN Number | US87978U2078 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove TPST